MVRx, Inc. is a Health Care startup founded in 2009, with a focus on advancing transcatheter therapy for resilient heart health and optimal blood flow. The company's slogan, "Advanced transcatheter therapy for resilient heart health and optimal blood flow," reflects its commitment to innovation in the medical field.
MVRx has developed the ARTO System, a transcatheter annular reduction therapy designed to address mitral valve regurgitation associated with congestive heart failure. This specialized endovascular treatment aims to improve blood flow throughout the body by reducing the backward flow through the mitral valve.
The ARTO System works by reshaping the mitral annulus and enhancing leaflet coaptation, achieved through the inward displacement of the septal and lateral walls, thereby shortening the minor axis of the mitral valve. This procedure restores proper anatomic relationships and reduces regurgitation, offering a potential solution for patients with these cardiac conditions.
The company recently secured a $5.88M Venture Round investment on 06 April 2020, signaling confidence from investors in MVRx's innovative approach to addressing cardiovascular health challenges. With a focus on leveraging advanced technology to improve patient outcomes, MVRx is poised to make a significant impact in the field of cardiac care.
Cardiac Dimensions
